financetom
Personal Finance
financetom
/
Personal Finance
/
TATA AIG launches 'Health Supercharge' with sum insured ranging from ₹5 lakh to ₹20 lakh
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TATA AIG launches 'Health Supercharge' with sum insured ranging from ₹5 lakh to ₹20 lakh
Nov 29, 2023 9:31 AM

TATA AIG General Insurance Company has launched “Health Supercharge” with a sum insured ranging from ₹5 lakh to ₹20 lakh. Customers can choose from options of two plan variants (Value Plan and Geo Plan), basis their geographical location, and other optional benefits offered under the product as per one’s requirement.

Live TV

Loading...

Speaking about the new health insurance policy – TATA AIG Health Supercharge, Santosh Puri, Senior Vice President – Health Product & Process, TATA AIG General Insurance said, “With the launch of Health Supercharge, we will be able to provide policyholders with 5X more coverage for their well-being."

Key highlights of Tata AIG Health Supercharge include:

The product introduces an enhanced level of coverage through a 5X supercharge bonus. This policy offers on each renewal a bonus of 50% of base sum insured of the expiring policy and accumulating maximum bonus up to 500% of the base sum insured in any policy year irrespective of claims.

Families below the age of 40 years or below at the time of first policy inception can benefit from an extra 5% discount which is also applicable upon policy renewals, irrespective of claims, the insurance company said.

The policy offers tailored flexibility with two plan variants (Value Plan & Geo Plan), and optional benefits such as unlimited restore, reduction of Pre-Existing Disease (PED) waiting period for named ailments.

Preventive annual health check-up can be availed by the insured persons once in a policy year, irrespective of claims, by paying an additional premium.

(Edited by : Anshul)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Keeps Buy Opinion On Shares Of Pfizer Inc.
Research Alert: CFRA Keeps Buy Opinion On Shares Of Pfizer Inc.
Aug 5, 2025
11:10 AM EDT, 08/05/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After reviewing Q2 results, we maintain our target price at $28, 9.2x our 2026 EPS estimate, a discount to PFE's historical forward P/E average. We raise our 2025 EPS view...
Research Alert: CFRA Reiterates Hold Opinion On Shares Of Molson Coors Beverage Company
Research Alert: CFRA Reiterates Hold Opinion On Shares Of Molson Coors Beverage Company
Aug 5, 2025
11:30 AM EDT, 08/05/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our 12-month target by $7 to $48, based on a 2026 P/E of 8.3x, a justified discount to TAP's 5-year average forward P/E of 11.7x. We lower our...
Research Alert: CFRA Keeps Buy Opinion On Shares Of Cenovus Energy
Research Alert: CFRA Keeps Buy Opinion On Shares Of Cenovus Energy
Aug 5, 2025
11:15 AM EDT, 08/05/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: Our 12-month target price of CAD 24, up CAD 1, reflects a 4.8x multiple of EV to projected '26 EBITDA, in line with CVE's historical forward average. We cut our...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Teleflex Incorporated
Research Alert: CFRA Maintains Hold Opinion On Shares Of Teleflex Incorporated
Aug 5, 2025
12:15 PM EDT, 08/05/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We cut our target price by $11 to $125, 8.4x our 2026 EPS estimate, a discount to historical due to soft Urolift demand. Q2 EPS of $3.73 vs. $3.42, beat...
Copyright 2023-2025 - www.financetom.com All Rights Reserved